Redefining the extension of Healthspan at the Cellular Level
At Mogling Bio, we are pioneering pharmacological solutions to restore the function of aged and exhausted cells—particularly stem cells—addressing a root cause of tissue degeneration and age-related diseases.
Our platform targets cellular aging to unlock new pathways for regenerative health, with the ultimate goal of compressing morbidity and extending Healthspan.
We are advancing a new class of therapeutics positioned at the intersection of aging biology and regenerative medicine—backed by science, driven by impact.
Science
Targeting Cdc42 to reverse Cellular Aging at its Core
At Mogling Bio, we are targeting a key driver for aging: Cdc42. This small but powerful protein becomes hyperactive as we age, disrupting cellular architecture and triggering functional decline. We are developing innovative therapies to specifically reduce the age-associated overactivation of Cdc42. By dialing down Cdc42 activity, we restore order inside aging cells to rejuvenate (stem) cell function to engineering rejuvenation.
This breakthrough approach unlocks the potential to combat a wide range of age-related diseases, from osteoporosis and immune dysfunction to blood disorders and neurodegeneration.
Team
Partnering
If you’re interested in exploring partnering or investment opportunities with Mogling Bio, please contact:
Mogling Bio Business Development
info@moglingbio.com
Interested In Meeting?
Find Us Here:
LSX World congress, Boston USA , Sep 11-12 2024
Longevity Investors Conference, Gstaad, Switzerland Sep 24-27 2024
Bio Europe, Stockholm, Nov 4-6 2024